Overcoming resistance to BRAFV600E inhibition in melanoma by deciphering and targeting personalized protein network alterations
Abstract BRAFV600E melanoma patients, despite initially responding to the clinically prescribed anti-BRAFV600E therapy, often relapse, and their tumors develop drug resistance. While it is widely accepted that these tumors are originally driven by the BRAFV600E mutation, they often eventually diverg...
Saved in:
Main Authors: | S. Vasudevan, E. Flashner-Abramson, Heba Alkhatib, Sangita Roy Chowdhury, I. A. Adejumobi, D. Vilenski, S. Stefansky, A. M. Rubinstein, N. Kravchenko-Balasha |
---|---|
Format: | article |
Language: | EN |
Published: |
Nature Portfolio
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/3fa3ce4bd8c843c780d29b16c0e89e36 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
IMMUNOHISTOCHEMICAL EXPRESSION OF BRAFV600E IN MELANOMA CASES
by: Muhammad Umer Ch, et al.
Published: (2021) -
BRAFV600E negatively regulates the AKT pathway in melanoma cell lines.
by: Brenden Chen, et al.
Published: (2012) -
SIRT6 haploinsufficiency induces BRAFV600E melanoma cell resistance to MAPK inhibitors via IGF signalling
by: Thomas Strub, et al.
Published: (2018) -
Synergistic activation of mutant TERT promoter by Sp1 and GABPA in BRAFV600E-driven human cancers
by: Yongxing Wu, et al.
Published: (2021) -
BRAFV600E induces reversible mitotic arrest in human melanocytes via microrna-mediated suppression of AURKB
by: Andrew S McNeal, et al.
Published: (2021)